Knowledge, Attitude and Perception of Consumers and Stakeholders on Counterfeit Drugs and Anti-Counterfeit Technology in Nigeria

Download Article

DOI: 10.21522/TIJPH.2013.12.01.Art039

Authors : Olakunle Daniel Olaniran, Azeez Akintunde Yusuf, Felix Olaniyi Sanni

Abstract:

The threat of counterfeiting medicines is probably growing, particularly in poorer countries with weak regulatory mechanisms and poorly monitored distribution networks. Various interventions, including innovative technologies, have been used to solve problems. The study used a quantitative design method adopting a hybrid quantitative method such as desk, online and physical interviews approach. The selected states for the study are Lagos, Kano, Anambra and FCT Abuja. Data were obtained using structured questionnaires with mainly closed-ended questions and analysed using SPSS (IBM-SPSS version 21). The findings show that the highest proportion of consumers who have heard about counterfeit or fake drugs before was from Lagos (97.1%). The study also found that stakeholders know highly about fake/counterfeit drugs (94.3%). The results show that 62.0% of consumers knew about drug anti-counterfeiting technology, and most stakeholders (79.0) knew about NAFDAC Anti- Counterfeiting Interventions. However, respondents from Lagos had the highest level of awareness (77.3%) of the Anti-Counterfeiting Interventions. The results also revealed that stakeholders exhibited a positive perception of NAFDAC’s innovative techs., (TruScan, RFID, GPHF MINILABS, Black Eye, Others) to curb fake drugs. The findings emphasise raising awareness, implementing effective anti- counterfeiting strategies, and addressing financial limitations to protect public health and combat Nigeria’s growing threat of fake drugs.

References:

[1]  Feldschreiber, P. (2009). Public health issues with counterfeit medicines. Clinical Medicine, Journal of the Royal College of Physicians of London, 9(1), 63–64. https://doi.org/10.7861/clinmedicine.9-1-63.

[2]  Mackey, T. K., & Liang, B. A. (2013). Improving global health governance to combat counterfeit medicines: A proposal for a UNODC-WHO-Interpol trilateral mechanism. BMC Medicine, 11(1). https://doi.org/10.1186/1741-7015-11-233.

[3]  WHO. (2017). A study on Public Health and Socio-economic Impact of Substandard and Falsified Medical Products. World Health Organization 2017, 1–67.

[4]  Ubajaka, C. F., Obi-okaro, A. C., Emelumadu, O. F., Azumarah, M. N., Ukegbu, A. U., & Ilikannu, S.

O. (2016). Factors Associated with Drug Counterfeit in Nigeria : A Twelve Year Review. 12(4), 1–8. https://doi.org/10.9734/BJMMR/2016/21342.

[5]  Amadi, L., & Amadi2, M. (2014). Sustainable Drug Consumption, Regulatory Dynamics and Fake

Drug Repositioning in Nigeria: A Case of NAFDAC.

Journal of Scientific Issues, 2(9), 412–419.

[6]  NAFDAC. (2010). The National Agency for Food and Drug Administration and Control (NAFDAC) Mobile Authentication Service Scheme Guidelines for the Procurement and Management of the NAFDAC Mobile Authentication Service (MAS) Scheme. NAFDAC’s MAS Implementation Guide.

[7]  NAFDAC. (2017). NAFDAC Anti-counterfeiting Strategies.           https://www.nafdac.gov.ng/about- nafdac/nafdac-anti-counterfeiting-strategies/.

[8]  United     Nations.     (2023).     The     Sustainable Development Goals in Nigeria.

[9]  Alfadl, A. A. (2018). Perspective, Knowledge, Attitude, and Belief of Various Stakeholders on Medicines Quality: Counterfeit and Substandard Medicines. In Social and Administrative Aspects of Pharmacy in Low-and Middle-Income Countries: Present Challenges and Future Solutions. Elsevier. https://doi.org/10.1016/B978-0-12-811228-1.00021- 2.

[10] Naing et al. (2006). Practical Issues in Calculating the Sample Size for Prevalence Studies.

[11] Groarke L. (2001). Anecdotal Reasoning. https://scholar.uwindsor.ca/cgi/viewcontent.cgi?refe rer=&httpsredir=1&article=1637&context=ossaarchi ve.

[12] Egwu, P. E. (2018). Audience exposure and attitude towards NAFDAC’S ‘Mobile Authentication Service’ (MAS) campaigns in three selected south east states. In Energies (Vol. 6, Issue 1). https://www.google.com/url?sa=t&rct=j&q=&esrc= s&source=web&cd=&cad=rja&uact=8&ved=2ahU KEwjFkJvyhuj- AhWTM8AKHc7iB5oQFnoECBcQAQ&url=http% 3A%2F%2Frepository.unn.edu.ng%2Fbitstream%2 Fhandle%2F123456789%2F9142%2FEgwu%2C%2 520Patrick%2520Ejike%2520Jnr.pdf%3Fsequ.

[13] Akinyandenu, O. (2013). Counterfeit drugs in Nigeria: A threat to public health. African Journal of Pharmacy and Pharmacology, 7(36), 2571–2576. https://doi.org/10.5897/ajpp12.343.

[14] Onuh, G., Hinga, S. K., Nyamweya, B. M., & Aderemi, A. A. (2022). Assessment of consumers ‘ awareness and ability to identify counterfeit drugs in developing countries in Africa – a cross sectional study    based     on           online    survey.   1–15. https://www.researchsquare.com/article/rs- 998393/v2.

[15] Mhando, L., Jande, M. B., Liwa, A., Mwita, S., & Marwa, K. J. (2016). Public Awareness and Identification of Counterfeit Drugs in Tanzania: A View on Antimalarial Drugs. Advances in Public Health, 2016,      1–8. https://doi.org/10.1155/2016/6254157.

[16] Ono, G. N. (2020). Assessment of Consumers’ Awareness and Exposure Levels to NAFDAC Media

Campaign in South East Nigeria. Research on Humanities and Social Sciences, 10(4), 19–25. https://doi.org/10.7176/rhss/10-4-04.

[17] Wakefield, M. A., Loken, B., & Hornik, R. C. (2010). Use of mass media campaigns to change health behaviour. The Lancet, 376(9748), 1261– 1271.   https://doi.org/10.1016/S0140- 6736(10)60809-4.

[18] Uzochukwu Elizabeth, C. (2017). Audience awareness and use of mobile authentication service (MAS) in identifying fake and substandard drugs in Nigeria. Journal of African Studies. Journal of African Studies, 77(11), 46–66.

[19] Akunyili, D. (2010). The challenges faced by NAFDAC in the National regulatory process as it relates to essential drugs for prevention of maternal and newborn deaths in Nigeria. Tropical Journal of Obstetrics and Gynaecology, 27(April 2010).

[20] Hall, C. (2012). Technology for combating counterfeit medicine. Pathogens and Global Health, 106(2),            73–76. https://doi.org/10.1179/204777312X1341924593948 5.

[21] Modi, S., & Wadhwa, S. (2009). Multiple Strategies   and         Technologies        to            Combat Counterfeit,Computer Sciences Corporation (CSC). 1–15. http://assets1.csc.com/innovation/downloads/CSCPa pers2009CounterfeitDrugs.pdf.

[22] Bansal, D., Malla, S., Gudala, K., & Tiwari, P. (2013). Anti-counterfeit technologies: A pharmaceutical industry perspective. Scientia Pharmaceutica,                  81(1),               1–13. https://doi.org/10.3797/scipharm.1202-03.